NUCALA Drug Profile

Summary for Tradename: NUCALA

High Confidence Patents:	3
Applicants:	1
BLAs:	2
Recent Clinical Trials:	See clinical trials for NUCALA

Recent Clinical Trials for NUCALA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Rigshospitalet, Denmark	PHASE4
GlaxoSmithKline	PHASE4
Centre hospitalier de l'Université de Montréal (CHUM)	Phase 4

See all NUCALA clinical trials

Pharmacology for NUCALA

Mechanism of Action	Interleukin-5 Antagonists
Established Pharmacologic Class	Interleukin-5 Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for NUCALA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for NUCALA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Llc	NUCALA	mepolizumab	For Injection	125526	10,870,695	2036-08-22	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Llc	NUCALA	mepolizumab	For Injection	125526	5,693,323	2015-06-06	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Llc	NUCALA	mepolizumab	For Injection	125526	6,129,913	2015-12-22	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Llc	NUCALA	mepolizumab	Injection	125526	10,870,695	2036-08-22	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Llc	NUCALA	mepolizumab	Injection	125526	5,693,323	2015-06-06	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for NUCALA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Llc	NUCALA	mepolizumab	For Injection	125526		2037-03-16	Patent claims search
Glaxosmithkline Llc	NUCALA	mepolizumab	For Injection	125526		2036-05-12	Patent claims search
Glaxosmithkline Llc	NUCALA	mepolizumab	For Injection	125526		2036-08-10	Patent claims search
Glaxosmithkline Llc	NUCALA	mepolizumab	For Injection	125526		2037-08-14	Patent claims search
Glaxosmithkline Llc	NUCALA	mepolizumab	For Injection	125526		2037-10-27	Patent claims search

International Patents for NUCALA

Country	Patent Number	Estimated Expiration
Japan	2018526369
Peru	20181176
Japan	6821659
Uruguay	36868
Colombia	2018001840

Market Dynamics and Financial Trajectory for NUCALA (Mepolizumab)

Last updated: January 19, 2026

Executive Summary

NUCALA (mepolizumab), developed by GlaxoSmithKline (GSK), is a monoclonal antibody targeting interleukin-5 (IL-5), primarily used in severe eosinophilic asthma and other eosinophilic conditions such as eosinophilic granulomatosis with polyangiitis (EGPA). Since its approval in 2015, NUCALA has established a solid foothold in the biologic asthma segment, driven by high unmet medical needs, regulatory approvals, and expanding indications. This report analyzes the market dynamics and evaluates its financial trajectory amid a competitive landscape, evolving regulations, and scientific advancements.

---

Market Overview of NUCALA

Indications and Approved Uses

Indication	Approval Date	Key Details
Severe eosinophilic asthma	May 2015	Subcutaneous injection, chronic management
Eosinophilic granulomatosis with polyangiitis (EGPA)	Nov 2017	ASO (Accelerated Supplemental Approval)
Hypereosinophilic syndrome (HES)	Dec 2018	Approved in certain jurisdictions
Chronic rhinosinusitis with nasal polyps (CRSwNP)	Feb 2019	Approved in the US and EU

Market Size and Growth Drivers

Parameter	2023 Estimate	Projected Growth (2023-2028)
Global asthma prevalence	262 million (Gtm Research, 2022)	CAGR: 4.4% (2022-2028)
Severe eosinophilic asthma patients	~8 million globally (GSK data)	CAGR: 11.2% (2023-2028, due to unmet need)
Biologic asthma therapy market value	~$21 billion (2022)	CAGR: 7-8% (2022-2028)
NUCALA market share in biologic asthma	~25-30% (GSK, 2023)	Expected to stabilize or slightly increase

---

Market Dynamics

Key Factors Influencing NUCALA's Market

Unmet Medical Needs and Clinical Efficacy

• High Efficacy: NUCALA demonstrates significant reductions in exacerbations and corticosteroid use, especially in patients with eosinophilic asthma.
• Patient Population: Only a subset of severe asthma patients with eosinophilia benefit, limiting market size but ensuring high-value patient segments.

Competitive Landscape

Competitors	Major Products	Key Features	Approval Dates
Sanofi/Regeneron	Dupixent (dupilumab)	Targets IL-4/IL-13, broader indication in asthma	March 2018 (for asthma)
AstraZeneca	Fasenra (benralizumab)	IL-5 receptor antagonist, alternative mechanism	November 2017 (US)
Novartis	Leqvio (inclisiran) — Not directly comparable, focus on another indication

• Market Share Trends: NUCALA competes primarily with Fasenra and Dupixent in eosinophilic asthma. Dupixent’s broader indication portfolio and oral administration advantage impact NUCALA's market penetration.

Regulatory and Pricing Policies

• High healthcare costs drive importance of reimbursement policies.
• In the US, NUCALA's list price (~$32,500/year) impacts adoption; insurers favor value-based arrangements.
• EU and other regions face variability in reimbursement, influencing sales.

Pricing and Reimbursement Dynamics

Region	Pricing (USD/year)	Status of Reimbursement	Impact on Market Penetration
United States	~$32,500	Reimbursed via insurance, prior authorization required	High, but selective coverage
European Union	~$29,000	Variable; national health services determine reimbursement	Variable, slower growth
Japan	~$28,000	Reimbursed through national health insurance	Growing adoption

Technological and Scientific Trends

• Biologic Innovation: Development of subcutaneous formulations increases patient convenience.
• Precision Medicine: Identification of eosinophilic biomarkers enhances targeted therapy, potentially increasing NUCALA's market share.
• Combination Therapies: Explorations into combination with other biologics or as part of multi-target approaches may influence future adoption.

---

Financial Trajectory of NUCALA

Revenue Performance

Year	Global Sales (USD Millions)	Growth Rate	Key Factors
2015	~$215	—	Launch year
2018	~$1,007	+368%	Expanded indications, better market acceptance
2020	~$1,565	+55.4%	COVID-19 impact mitigated through telehealth services
2022	~$2,300 (estimated)	+47.1%	Market expansion, international growth

Note: 2022 figures are estimated, based on industry reports and GSK financial disclosures.

Forecasting 2023-2028

Year	Projected Revenue (USD Millions)	Assumptions
2023	~$2,500 - $2,700	Steady market growth, new approvals, and indications
2024	~$2,800 - $3,100	Increased penetration, potential new indications
2025	~$3,200 - $3,500	Market saturation in key regions; incremental gains
2026-2028	CAGR 5-8%	Ongoing competition, technological innovations, biosimilars

Profitability Trends

• GSK's Gross Margins: Historically ~70–75%
• R&D Investment: ~15% of revenue (GSK’s 2022 R&D expenditure was £4.7 billion)
• Cost of Goods Sold (COGS): ~20-25% of revenue
• Operating Margin: Maintaining around 20-25% with growth

---

Comparison with Competing Biologics

Drug	Target	Indications	Market Share (2023)	Pricing (USD/year)	Approval Date
NUCALA (mepolizumab)	IL-5 inhibitor	Eosinophilic asthma, EGPA	Approx. 25-30%	~$32,500	2015
Fasenra (benralizumab)	IL-5 receptor antagonist	Severe eosinophilic asthma	Approaching 20%	~$30,800	2017
Dupixent (dupilumab)	IL-4/IL-13 inhibitor	Eosinophilic asthma, atopic dermatitis	25-35% in asthma COVID pandemic	~$37,000	2018

---

Regulatory and Policy Influences

• FDA and EMA Approvals: Timely approvals driven by unmet need.
• Reimbursement Policies: Shift towards value-based models influence pricing and sales.
• Orphan Drug Status & Fast Track: Facilitates accelerated reviews and exclusivity, impacting R&D timelines and market exclusivity.

---

Future Opportunities and Risks

Opportunities

• Expanded Indications: Chronic rhinosinusitis, HES, and emerging eosinophilic diseases.
• Geographic Expansion: Markets like China, India offer growth potentials.
• Biologic Development: Next-generation formulations and biosimilars may enable cost reductions and wider access.
• Combination Therapy Approaches: Synergistic therapies for complex eosinophilic conditions.

Risks

• Patent Expiry and Biosimilar Entry: Patent expiration expected around 2027-2030; biosimilar entry could pressure prices.
• Intense Competition: From Fasenra, Dupixent, and emerging biologics.
• Pricing and Reimbursement Changes: Healthcare reforms may limit pricing flexibility.
• Market Penetration Barriers: High treatment costs and patient access hurdles.

---

Conclusion

NUCALA’s market dynamics are shaped by its targeted mechanism of action, expanding therapeutic indications, and competitive pressures. Its financial trajectory demonstrates steady growth, with projections indicating continued revenue expansion driven by market penetration, geographic expansion, and new indications. Nonetheless, risks from biosimilar competition and policy reforms necessitate strategic positioning by GSK.

---

Key Takeaways

• NUCALA remains a leading IL-5 inhibitor with a strong foothold in eosinophilic asthma.
• Market growth is supported by increasing prevalence of eosinophilic conditions and biologic adoption.
• Competition and biosimilar threat will impact future pricing and market share.
• GSK’s pipeline expansion and regulatory strategies are critical to sustain growth.
• Geographical and indication diversification present significant upside opportunities.

---

FAQs

1. What are the primary clinical advantages of NUCALA over competitors?
   NUCALA offers a proven reduction in exacerbations and oral corticosteroid dependency in eosinophilic asthma with a favorable safety profile. Its subcutaneous administration enhances patient convenience.

2. When is NUCALA likely to face biosimilar competition?
   Biosimilars could enter the market post-2027, assuming patent protections expire, potentially impacting prices and market share.

3. Which regions are key for NUCALA's future growth?
   Asian markets like China and India, along with expanding European and Latin American markets, present substantial growth opportunities due to increasing healthcare access and unmet clinical needs.

4. How does NUCALA compare cost-wise to other biologics in the same class?
   Cost per patient per year is similar among IL-5 inhibitors (~$30,000 - $33,000), but value-driven reimbursement models influence uptake.

5. What emerging indications could expand NUCALA’s market?
   Conditions like HES, eosinophilic esophagitis, and chronic cough are under investigation or early approval stages, offering future growth pathways.

---

References

[1] GSK Annual Reports (2015-2022)
[2] GSK Product Labeling & Regulatory disclosures
[3] Market Research Reports (Gtm Research, EvaluatePharma)
[4] Regulatory Agency Approvals (FDA, EMA)
[5] Industry Analysis and Expert Commentary (2023)